Report cover image

Global Peptide-Radionuclide Conjugates (PRCs) Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 192 Pages
SKU # APRC20283458

Description

Summary

According to APO Research, The global Peptide-Radionuclide Conjugates (PRCs) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptide-Radionuclide Conjugates (PRCs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Peptide-Radionuclide Conjugates (PRCs) include Grand Pharmaceutical, Novartis, Telix Pharmaceutical, RadioMedix, ITM Radiopharma and Curium Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide-Radionuclide Conjugates (PRCs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptide-Radionuclide Conjugates (PRCs), also provides the sales of main regions and countries. Of the upcoming market potential for Peptide-Radionuclide Conjugates (PRCs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide-Radionuclide Conjugates (PRCs) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide-Radionuclide Conjugates (PRCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Peptide-Radionuclide Conjugates (PRCs) sales, projected growth trends, production technology, application and end-user industry.

Peptide-Radionuclide Conjugates (PRCs) Segment by Company

Grand Pharmaceutical
Novartis
Telix Pharmaceutical
RadioMedix
ITM Radiopharma
Curium Pharma
Peptide-Radionuclide Conjugates (PRCs) Segment by Type

Diagnostic PRCs
Therapeutic PRCs
Peptide-Radionuclide Conjugates (PRCs) Segment by Application

Prostate Cancer
Neuroendocrine Tumors
Other
Peptide-Radionuclide Conjugates (PRCs) Segment by Region

North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Radionuclide Conjugates (PRCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide-Radionuclide Conjugates (PRCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Radionuclide Conjugates (PRCs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Peptide-Radionuclide Conjugates (PRCs) in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Peptide-Radionuclide Conjugates (PRCs) manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide-Radionuclide Conjugates (PRCs) sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Peptide-Radionuclide Conjugates (PRCs) Market by Type
1.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Diagnostic PRCs
1.2.3 Therapeutic PRCs
1.3 Peptide-Radionuclide Conjugates (PRCs) Market by Application
1.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Prostate Cancer
1.3.3 Neuroendocrine Tumors
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Peptide-Radionuclide Conjugates (PRCs) Market Dynamics
2.1 Peptide-Radionuclide Conjugates (PRCs) Industry Trends
2.2 Peptide-Radionuclide Conjugates (PRCs) Industry Drivers
2.3 Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges
2.4 Peptide-Radionuclide Conjugates (PRCs) Industry Restraints
3 Global Market Growth Prospects
3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Estimates and Forecasts (2020-2031)
3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region
3.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2020-2025)
3.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2026-2031)
3.2.4 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2020-2031)
3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Estimates and Forecasts 2020-2031
3.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region
3.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2020-2025)
3.4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2026-2031)
3.4.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers
4.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers (2020-2025)
4.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers
4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers (2020-2025)
4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Price by Manufacturers (2020-2025)
4.4 Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers, Product Type & Application
4.7 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Peptide-Radionuclide Conjugates (PRCs) Market CR5 and HHI
4.8.2 2024 Peptide-Radionuclide Conjugates (PRCs) Tier 1, Tier 2, and Tier 3
5 Peptide-Radionuclide Conjugates (PRCs) Market by Type
5.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type
5.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2020-2031)
5.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type
5.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020-2031) & (K Units)
5.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2020-2031)
5.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Type
6 Peptide-Radionuclide Conjugates (PRCs) Market by Application
6.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application
6.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2020-2031)
6.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application
6.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020-2031) & (K Units)
6.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2020-2031)
6.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Application
7 Company Profiles
7.1 Grand Pharmaceutical
7.1.1 Grand Pharmaceutical Comapny Information
7.1.2 Grand Pharmaceutical Business Overview
7.1.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
7.1.5 Grand Pharmaceutical Recent Developments
7.2 Novartis
7.2.1 Novartis Comapny Information
7.2.2 Novartis Business Overview
7.2.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
7.2.5 Novartis Recent Developments
7.3 Telix Pharmaceutical
7.3.1 Telix Pharmaceutical Comapny Information
7.3.2 Telix Pharmaceutical Business Overview
7.3.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
7.3.5 Telix Pharmaceutical Recent Developments
7.4 RadioMedix
7.4.1 RadioMedix Comapny Information
7.4.2 RadioMedix Business Overview
7.4.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
7.4.5 RadioMedix Recent Developments
7.5 ITM Radiopharma
7.5.1 ITM Radiopharma Comapny Information
7.5.2 ITM Radiopharma Business Overview
7.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
7.5.5 ITM Radiopharma Recent Developments
7.6 Curium Pharma
7.6.1 Curium Pharma Comapny Information
7.6.2 Curium Pharma Business Overview
7.6.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
7.6.5 Curium Pharma Recent Developments
8 North America
8.1 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
8.1.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020-2031)
8.1.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020-2031)
8.1.3 North America Peptide-Radionuclide Conjugates (PRCs) Price by Type (2020-2031)
8.2 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
8.2.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020-2031)
8.2.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020-2031)
8.2.3 North America Peptide-Radionuclide Conjugates (PRCs) Price by Application (2020-2031)
8.3 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
8.3.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Peptide-Radionuclide Conjugates (PRCs) Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
9.1.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020-2031)
9.1.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020-2031)
9.1.3 Europe Peptide-Radionuclide Conjugates (PRCs) Price by Type (2020-2031)
9.2 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
9.2.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020-2031)
9.2.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020-2031)
9.2.3 Europe Peptide-Radionuclide Conjugates (PRCs) Price by Application (2020-2031)
9.3 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
9.3.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Peptide-Radionuclide Conjugates (PRCs) Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
10.1.1 China Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020-2031)
10.1.2 China Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020-2031)
10.1.3 China Peptide-Radionuclide Conjugates (PRCs) Price by Type (2020-2031)
10.2 China Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
10.2.1 China Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020-2031)
10.2.2 China Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020-2031)
10.2.3 China Peptide-Radionuclide Conjugates (PRCs) Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
11.1.1 Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020-2031)
11.1.2 Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020-2031)
11.1.3 Asia Peptide-Radionuclide Conjugates (PRCs) Price by Type (2020-2031)
11.2 Asia Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
11.2.1 Asia Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020-2031)
11.2.2 Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020-2031)
11.2.3 Asia Peptide-Radionuclide Conjugates (PRCs) Price by Application (2020-2031)
11.3 Asia Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
11.3.1 Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Peptide-Radionuclide Conjugates (PRCs) Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Market Size by Type
12.1.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2020-2031)
12.1.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2020-2031)
12.1.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Price by Type (2020-2031)
12.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Market Size by Application
12.2.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2020-2031)
12.2.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2020-2031)
12.2.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Price by Application (2020-2031)
12.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Market Size by Country
12.3.1 SAMEA Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Peptide-Radionuclide Conjugates (PRCs) Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Peptide-Radionuclide Conjugates (PRCs) Value Chain Analysis
13.1.1 Peptide-Radionuclide Conjugates (PRCs) Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process
13.2 Peptide-Radionuclide Conjugates (PRCs) Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
13.2.3 Peptide-Radionuclide Conjugates (PRCs) Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.